Investigation of immune cells in patients with obstructive sleep apnea

• Conditions: G47.31

• Registration Number: DRKS00025507
• Lead Sponsor: niversitätsmedizin der Johannes Gutenberg-Universität Mainz; Hals-, Nasen-, Ohrenklinik und Poliklinik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-20
• Study Completion: 2022-03-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patient in the Sleep Medicine Centre & Sleep Research Lab, Dept. of Otorhinolaryngology Head & Neck Surgery, University Medical Center Mainz;
Willingness to participate in the study;
Suspicion of Obstructive Sleep Apnea;
Snoring or daytime sleepiness or observed breathing interruptions during sleep or an AHI = 5 / h screened by an outpatient cardiorespiratory polygraph;
Currently no therapy for breathing-related sleep disorders (e.g. continuous positive airway pressure: CPAP);
No prior surgical procedure for OSA;
Age of the participant: > 18 years;
German and / or English language skills

Exclusion Criteria

Age of the participant: <18 years;
Existing pregnancy;
obesity (BMI> 35 kg / m²);
COPD (chronic obstructive pulmonary disease);
Heart failure;
Active malignant disease (5 years after finishing the corresponding therapy);
Hematological diseases (e.g. myelodysplastic syndrome);
diagnosed immune deficiency (e.g. AIDS);
Clinically relevant atherosclerosis (status post myocardial infarction, unstable angina pectoris, status post stroke, status post stenting of the coronary or peripheral arteries, status post surgery for peripheral arterial occlusive disease);
Chronic active inflammatory diseases (psoriasis, rheumatoid arthritis, Wegener's disease, sarcoidosis, syst. Lupus erythemadotes, other autoimmune diseases);
Active specific infections (e.g. tuberculosis);
Chronic therapy with oral steroids, immunosuppressants (e.g. cyclophosphamide, azathioprine or antibodies (immunotherapy);
Recently (within the last 4 weeks) history of vaccinations (e.g. against Covid-19)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Concentration / activity of blood CD4 + / CD8 + T cells

Secondary Outcome Measures

Name	Time	Method
Concentration / activity of blood dendritic cells (cDC1, cDC2, pDC)